Roche expresses confidence in 2012 prospects during AGM

Roche has expressed confidence in its 2012 business prospects during its recent annual general meeting (AGM).

Business leaders from the pharmaceutical company have stated that its commitment to innovation and its strong 2011 performance have positioned it well for future growth, while the proposed acquisition of Illumina would also offer various advantages.

According to the firm's most recent financial report, annual Roche sales for 2011 came to 42.53 billion Swiss francs (29.46 billion pounds).

Roche chief executive officer Severin Schwan said: "Following positive data from 17 of last year's late-phase trials, we are now even more strongly positioned to launch innovative new products that will deliver growth in the years ahead."

During the AGM, the company's shareholders approved Roche's 2011 annual report and financial statements, while ratifying a 25th consecutive dividend increase.

Franz Humer, Andre Hoffmann and Sir John Irving Bell were also re-elected to the board of directors following a vote.